Leading Cancer Researcher: They’re Ignoring My Research, Cancer Patients Must Know This!

Professor Thomas Seyfried presents a comprehensive theory of cancer origin centered on mitochondrial dysfunction. He argues that cancer fundamentally results from chronic damage to mitochondria—the cellular organelles responsible for energy production—rather than from genetic mutations as mainstream oncology suggests. When mitochondria become damaged through various environmental stressors (processed carbohydrates, inactivity, emotional stress, poor sleep, carcinogens, microplastics, and inflammation), cells lose their ability to produce energy efficiently through oxidative phosphorylation and compensate by reverting to ancient fermentation pathways that existed before oxygen became available in Earth's atmosphere. This compensatory mechanism leads to unregulated cell growth—cancer—because the damaged mitochondria can no longer properly signal when cells should divide.

Seyfried explains that cancer cells become dependent on two primary fuels: glucose and glutamine, which produce energy through fermentation rather than oxygen-dependent oxidative phosphorylation. This inefficiency forces tumors to become "greedy," consuming massive quantities of these fuels. The solution, according to Seyfried, involves metabolic therapy using a ketogenic diet to lower blood glucose while elevating ketone bodies. His Glucose-Ketone Index (GKI)—calculated by dividing blood glucose by blood ketone levels—serves as a quantitative measure of mitochondrial health. When patients maintain a low GKI (in the "green zone"), healthy cells thrive on ketones while cancer cells cannot utilize this fuel source due to their corrupted mitochondria, effectively starving tumors while nourishing the body.

Seyfried discusses how this metabolic approach can enhance conventional cancer treatments. When patients are in nutritional ketosis before chemotherapy, the metabolic stress on cancer cells increases drug efficacy, allowing physicians to use significantly lower doses while achieving better results and reducing toxicity to healthy cells. He presents case studies of long-term cancer survivors using metabolic therapy, including a glioblastoma patient who lived 10 years with an initially inoperable tumor and had multiple successful debulking surgeries.

The researcher explains why mainstream oncology has rejected mitochondrial theory, attributing it to the somatic mutation theory's dominance in medical education and cancer research funding structures. He argues that pharmaceutical companies profit from current treatments, creating institutional resistance to metabolic approaches. Seyfried emphasizes that his theory accounts for why cancer incidence is dramatically lower in traditional societies and in wild wolves compared to domesticated dogs—populations with different metabolic environments.

Addressing prevention and treatment policy, Seyfried advocates for patient education about the GKI chart rather than government mandates about food choices. He recommends lifestyle interventions including exercise, stress reduction, quality sleep, and avoiding highly processed carbohydrates and industrial chemicals. For cancer patients, he proposes a comprehensive approach combining metabolic therapy, repurposed drugs targeting glutaminolysis (like mebendazole), lower-dose chemotherapy during ketosis, and potentially immunotherapies once tumors are metabolically weakened. He emphasizes that while metabolic therapy may not "cure" cancer, it can significantly extend survival and improve quality of life compared to conventional approaches.